Evidence supporting the use of: Sulfated polysaccharide
For the health condition: Fibrosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Sulfated polysaccharides, particularly those derived from marine sources such as fucoidan (from brown seaweed) and carrageenan, have been studied for their potential anti-fibrotic properties. Scientific evidence, primarily from preclinical studies, suggests that these compounds may help in the management or prevention of fibrosis—a pathological process characterized by excessive deposition of extracellular matrix components, leading to tissue scarring and organ dysfunction. Sulfated polysaccharides are thought to exert anti-fibrotic effects by modulating key pathways involved in fibrosis, such as reducing the activity of transforming growth factor-beta (TGF-β), inhibiting fibroblast proliferation, suppressing inflammatory responses, and attenuating oxidative stress. Animal studies have demonstrated that administration of these polysaccharides can reduce fibrosis in organs such as the liver, lungs, and kidneys. For example, a number of studies have shown that fucoidan can decrease collagen deposition and improve liver function in models of liver fibrosis. However, most of the current evidence is limited to in vitro experiments and animal models, with only a few early-phase human trials available. As such, while there is a scientific rationale and promising preliminary data for the use of sulfated polysaccharides in supporting or treating fibrosis, robust clinical evidence in humans is still lacking. Ongoing research aims to clarify their efficacy, safety, and mechanisms of action in human fibrotic diseases.

More about Sulfated polysaccharide
More about Fibrosis

Products containing Sulfated polysaccharide

We currently have no products on Vitabase that contain this ingredient.